Related Experiment Video
Updated: Jul 12, 2026

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
Published on: October 2, 2014
Pharmacokinetic characterization of extracorporeal therapy
Abstract:
The efficiency of extracorporeal therapy with immobilized enzymes (reactive devices) and hemoperfusion cartridges (nonreactive devices) is evaluated in terms of a new pharmacokinetic parameter, the bioefficacy. A detailed analysis is provided in the former case, and it is shown how the bioefficacy can be calculated from a combined pharmacokinetic and reactor analysis. The theory is presented for evaluating bioefficacy in terms of linear pharmacokinetic models that view the reactor or other extracorporeal appliance as an artificial organ. Examples are drawn from recent work on methotrexate rescue with immobilized carboxypeptidase G1 and from literature data on the use of hemoperfusion to treat drug overdose to illustrate the calculations.
Related Concept Videos
Drug Concentration Versus Time Correlation
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the lowest drug...
Two-Compartment Open Model: Extravascular Administration
The absorption exponent (ka) indicates the speed at which the drug is...
Measurement of Bioavailability: Pharmacokinetic Methods
Extracorporeal Removal of Drugs: Peritoneal Dialysis and Hemodialysis
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

